Dupilumab-Associated Lymphoid Reactions Require Caution Dupilumab-Associated Lymphoid Reactions Require Caution
Retrospective study identifies potential for misdiagnosed mycosis fungoides and for dupilumab to fuel cutaneous lymphoid reactions that mimic mycosis fungoides in patients with atopic dermatitis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 30, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Chlormethine Gel for the Treatment of Mycosis Fungoides Chlormethine Gel for the Treatment of Mycosis Fungoides
Review the use of chlormethine gel, a topical antineoplastic agent, for the treatment of stage IA and IB mycosis fungoides-cutaneous T-cell lymphoma.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Mycosis Fungoides Hospitalizations Longer for Blacks, Hispanics Mycosis Fungoides Hospitalizations Longer for Blacks, Hispanics
Results are consistent with prior studies that have found Black and Hispanic patients have earlier and more severe disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 16, 2021 Category: Cancer & Oncology Tags: Dermatology News Source Type: news
HSCT in Advanced Stage Mycosis Fungoides and Sezary Syndrome HSCT in Advanced Stage Mycosis Fungoides and Sezary Syndrome
Is HSCT potentially curative for cutaneous T-cell lymphoma?Chinese Clinical Oncology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 29, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Journal Article Source Type: news
Skin Care Guidelines for Patients With Mycosis Fungoides Skin Care Guidelines for Patients With Mycosis Fungoides
Optimal cleansers, moisturizers, and bathing habits are reviewed in these skin care guidelines for patients with cutaneous lymphoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Low-dose, Low-frequency PUVA May Be Suitable for Maintenance Therapy in Mycosis Fungoides Low-dose, Low-frequency PUVA May Be Suitable for Maintenance Therapy in Mycosis Fungoides
In patients with early-stage mycosis fungoides, treatment and maintenance therapy with low-dose, low-frequency oral psoralen - UV-A (PUVA) may extend disease-free remission, a proof-of-concept study reveals.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 27, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
What Causes Post-Inflammatory Hypopigmentation?
Discussion
Hypopigmentation can be worrisome for many families because of cosmesis and the worry that “something is wrong.” The normal natural changes in skin-tone over the year due to different light exposure and wide variations within individuals is not something that many people are aware of.
Post-inflammatory hypopigmentation is a common cause of hypopigmentation. Vitiligo is the most common cause of depigmentation.
Vitiligo is an acquired, depigmenting disorder with typical lesions appearing as milky white macules with distinct margins that are not scaly. Hair (including eyebrows and eyelashes) can be dep...
Source: PediatricEducation.org - November 12, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma
Mogamulizumab (Poteligeo) is indicated for relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
FDA Approves Poteligeo (mogamulizumab-kpkc) for Mycosis Fungoides and S ézary Syndrome
August 8, 2018 -- The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S ézary syndrome (SS) after... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 8, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Approves New Drug for Cutaneous T-Cell Lymphomas FDA Approves New Drug for Cutaneous T-Cell Lymphomas
The FDA has granted approval for mogamulizumab-kpkc for adult patients with relapsed or refractory mycosis fungoides or S é zary syndrome.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA approves treatment for two rare types of non-Hodgkin lymphoma
FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or S ézary syndrome after at least one prior systemic therapy (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 8, 2018 Category: American Health Source Type: news
FDA approves treatment for two rare types of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. (Source: World Pharma News)
Source: World Pharma News - August 8, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Mycosis Fungoides and Sezary Syndrome
Mycosis Fungoides and S é zary Syndrome (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 16, 2018 Category: General Medicine Source Type: news
New tool predicts deadly form of rare cancer
(Brigham and Women's Hospital) A tool to accurately determine which early-stage patients are at risk of dying from mycosis fungoides and which patients are likely to only require conventional therapy is desperately needed. Investigators from Brigham and Women's Hospital have found that next-generation, high-throughput sequencing of a specific gene (T-cell receptor beta or TCRB) is a stronger predictor of which early-stage patients will develop aggressive, progressive MF than any other established factor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and S ézary Syndrome
A Guide for the Practicing OncologistThird Edition
CLICK HERE TO ACCESS THE WHITE PAPER (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Tags: Sponsored Resources Source Type: news
